Spero Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2025 Annual Meeting of Stockholders held on June 12, 2025. The filing details the election of directors, ratification of auditors, approval of executive compensation, and an amendment to the company's stock incentive plan.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Corporate Actions
- Stock Plan Amendment: Stockholders approved an amendment to the 2017 Stock Incentive Plan to increase the authorized share pool by 3,000,000 shares.
- Board Elections: Frank E. Thomas, Patrick Vink, M.D., and Esther Rajavelu were reelected as Class II directors until the 2028 annual meeting.
- Auditor Ratification: PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Executive Compensation: The advisory vote on the compensation of named executive officers was approved.
Outlook, Risks, and Management Commentary
The filing does not contain management commentary on future outlook, specific risks, contingencies, or unusual items. It strictly reports the outcomes of the shareholder vote.
Key Facts for Investor Verification
- Verify the total number of shares authorized under the amended 2017 Stock Incentive Plan.
- Review the definitive proxy statement filed on April 28, 2025, for details on the material features of the stock plan amendment.
- Note that approximately 71.57% of outstanding shares were present or represented by proxy at the meeting.
- Confirm the tenure of the reelected directors extends through the 2028 annual meeting.